ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs that will dramatically extend and improve the lives of patients in areas of high unmet need.With four internally discovered drugs in multiple biomarker guided clinical trials and an enriched proprietary kinase library from which to select additional drug candidates, ArQule is delivering on the potential of precision medicine by providing its patients with novel therapies for multiple hard to treat indications and its shareholders with a focused, highly efficient and cost effective research and development strategy. ArQule is led by a senior management team with significant clinical and commercial expertise that provides the leadership required to optimize its opportunities for success in a rapidly changing and highly competitive field. Source
No articles found.
Catalyst is focused on developing novel medicines to address serious medical condi...
Catalyst is focused on developing novel medicin...
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, de...
STAAR, which has been dedicated solely to ophth...
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...
Edesa Biotech Inc. is a clinical-stage biopharm...
WinSanTorâs mission is simple-develop a drug that works. We recognize that there...
WinSanTorâs mission is simple-develop a drug ...
Chiasma is focused on improving the lives of patients who face challenges associat...
Chiasma is focused on improving the lives of pa...
We discover and develop medicines to defeat neurodegeneration. The science is brea...
We discover and develop medicines to defeat neu...
argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...
argenx is a clinical-stage biotechnology compan...
Join the National Investor Network and get the latest information with your interests in mind.